Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer ...

(Reuters) -AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

June 18 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to ...